Neuropeutics is a pharmaceutical company developing targeted therapies to extend neurodegenerative disease patients’ survival and improve their quality of life. One shared pathology across the wide range of neurodegenerative diseases (e.g., Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)) is TDP-43 pathology, which is associated with causing neurotoxicity and neuronal loss.
At Neuropeutics, we have had great success in developing novel high-throughput in vitro and in vivo models of TDP-43 pathology. Using these models, we identified an effective small molecule “JRMS-22” reducing pathology by 30% after two weeks of treatment in a mouse model. Based on our mechanistic understanding of disease, we have developed a novel approach to modulate, prevent, and reverse TDP-43 aggregation. Currently, our team is working relentlessly to finish IND enabling studies in preparation for clinical testing in those living ALS as our initial beachhead market.
Intellectual Property
Fundraising
Are you developing and/or redesigning new green products, services, processes, and technologies that reduce environmental impact?
The i.d.e.a.™ Fund program focuses on supporting a more sustainable economy while fostering an inclusive and equitable growth in southern Ontario. Find out if you’re eligible to access up to $20,000 in matching seed funding and 30 hours of expert mentorship.
Applications are open from September 9 to September 30, 2024.
Since 2011, Innovation Factory’s LiONS LAIR has helped more than 150 startups launch and scale their businesses. This fall, join over 350 entrepreneurs, investors and thought leaders to network over dinner and drinks, celebrate innovation, and watch finalists pitch live to a panel of judges to win cash and in-kind prizes.
When: September 26, 2024 | 5:00pm – 9:00pm
Where: LiUNA Station – 360 James St. N, Hamilton, Ontario L8L 1H5